Jason T. Gammack
About Jason T. Gammack
Jason T. Gammack serves as the Chief Executive Officer, leading the company as it transitions from its early access program to a full commercial launch of its rapid enzymatic synthesis technology for complex clonal genes and gene fragments.
Jason T. Gammack CEO
Jason T. Gammack serves as the Chief Executive Officer. He took on this role as the company completed its early access program and prepared for a full commercial launch. His leadership is expected to drive the company forward as it advances in the field of rapid enzymatic synthesis for complex clonal genes and gene fragments.
Leadership Transition at the Company
The transition in leadership at the company sees Jason T. Gammack stepping into the role of CEO. The founding CEO, Dan Lin-Arlow, PhD, will stay with the company and transition to a new role as Chief Scientific Officer. This change aims to leverage Dan Lin-Arlow's deep scientific expertise while Jason T. Gammack takes on the executive leadership role.
Full Commercial Launch Preparation
Jason T. Gammack joined the company during a critical phase as it prepared for the full commercial launch of its rapid enzymatic synthesis technology. This technology focuses on the synthesis of complex clonal genes and gene fragments, marking a significant milestone in the company’s growth and commercial strategy.